Despite the initial heightened sensitivity of RB1-deficient malignancies to DNA damage, strategies involving combinations of DNA-damaging agents with inhibitors of DNA damage repair, such as poly-ADP ribose polymerase (PARP) inhibitors (PARPis), show promise in addressing RB1-deficient cancers [19,59,60]. This evidence concerns the gene RB1 and cancer.